To the full analysis
ICU Medical stock: growth
ICUIICU Medical reported $2.23B in revenue for fiscal 2025, down 6.4% on the prior year, up 11.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.5%
per year from 2006 to 2025, per share 10.3%
Earnings (Annual rate)
−17.1%
per year from 2006 to 2025, per share −19.4%
Free cash flow (Annual rate)
11.3%
per year from 2006 to 2025, per share 8.2%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 11.9% | 20.6% | 13.5% |
| Revenue per share | 8.3% | 15.4% | 10.3% |
| Earnings | −61.5% | −33.8% | −17.1% |
| Earnings per share | −62.8% | −36.6% | −19.4% |
| Free cash flow | −5.6% | 8.4% | 11.3% |
| Free cash flow per share | −8.6% | 3.7% | 8.2% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $201.61M | $25.66M | $12M |
| 2007 | $188.14M | $23.08M | $17.87M |
| 2008 | $204.73M | $24.3M | $18.88M |
| 2009 | $231.51M | $26.56M | $31.92M |
| 2010 | $284.58M | $30.93M | $9.92M |
| 2011 | $302.2M | $44.67M | $48.66M |
| 2012 | $316.87M | $41.28M | $45.97M |
| 2013 | $313.72M | $40.42M | $44.53M |
| 2014 | $309.26M | $26.34M | $43.05M |
| 2015 | $341.67M | $44.99M | $40.93M |
| 2016 | $379.37M | $63.08M | $65.39M |
| 2017 | $1.29B | $68.64M | $74.74M |
| 2018 | $1.4B | $28.79M | $59.44M |
| 2019 | $1.27B | $101.04M | −$4.12M |
| 2020 | $1.27B | $86.87M | $122.36M |
| 2021 | $1.32B | $103.14M | $186.37M |
| 2022 | $2.28B | −$74.29M | −$161.46M |
| 2023 | $2.26B | −$29.66M | $72.53M |
| 2024 | $2.38B | −$117.69M | $124.66M |
| 2025 | $2.23B | $732K | $91.8M |
Revenue by region
Where ICU Medical, Inc. generates its revenue.
- United States61%
- EMEA18%
- Asia Pacific10%
- Other10%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| United States | $1.46B | $1.44B | $1.53B | $1.36B | 60.8% |
| EMEA | $367.41M | $373.57M | $393.53M | $411.68M | 18.5% |
| Asia Pacific | $257.21M | $241.7M | $232M | $232.9M | 10.4% |
| Other | $195.31M | $203.84M | $224.41M | $229.32M | 10.3% |
| Total revenue | $2.28B | $2.26B | $2.38B | $2.23B | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Overvalued since 10 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.